CEO Nadim Ahmed caught up with Brad Loncar of BiotechTV at #ASCO24 to discuss data Cullinan presented at this year’s conference & strategic expansion into autoimmune diseases. Check out the interview and learn more about Cullinan’s strategy and pipeline: https://bit.ly/455o5LY
𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟒: The Cullinan Therapeutics CEO Nadim Ahmed discusses two data sets at #ASCO24 and the rationale for a T-cell engager for autoimmune disease. He describes #ASCO24 data from today for CLN-619 and zipalertinib, and discusses taking a CD19/CD3 into the clinic for lupus. Full video: https://lnkd.in/gUM8eTKM BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent